Drug intelligence / Profile preview

MERRICAL

Development stage
Preclinical
Lead developer
Brigham and Women's Hospital
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

MERRICAL (Macrophage Enriched lncRNA Regulates Inflammation, Chemotaxis, and AtheroscLerosis) is a macrophage-enriched long non-coding RNA (lncRNA) that plays a critical role in the development of diabetes-associated atherosclerosis. It is nuclear-localized and significantly upregulated in intimal lesions during disease progression. MERRICAL functions through an *in-cis* regulatory mechanism, interacting with the histone modification enzyme H3K4me3 to modulate the expression of neighboring chemokine genes *Ccl3* and *Ccl4*. By regulating these genes, MERRICAL controls macrophage chemotaxis and pro-inflammatory responses. Experimental systemic knockdown of MERRICAL has been shown to significantly reduce atherosclerotic lesion formation and leukocyte recruitment in mouse models, suggesting its potential as a therapeutic target for vascular inflammation in diabetes.

Other names
Macrophage Enriched lncRNA Regulates Inflammation, Chemotaxis, and AtheroscLerosis
02

Targets

CCL4 (C-C motif chemokine ligand 4)CCL3H3K4me3 (Histone H3 lysine 4 trimethylation)

Beyond the preview

Go deeper on MERRICAL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MERRICAL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call